MorphoSys in-licenses first clinical compound from Xencor
In its first in-licensing of a clinical compound, MorphoSys of Germany has obtained a worldwide exclusive licence to a monoclonal antibody in Phase I development from US-based Xencor.
In its first in-licensing of a clinical compound, MorphoSys of Germany has obtained a worldwide exclusive licence to a monoclonal antibody in Phase I development from US-based Xencor.